No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ABT241227P120000
- 6.50
- -0.45-6.47%
15min DelayClose Dec 23 16:00 ET
6.50High6.50Low
6.50Open6.95Pre Close1 Volume0 Open Interest120.00Strike Price650.00Turnover51.79%IV0.71%PremiumDec 27, 2024Expiry Date5.69Intrinsic Value100Multiplier4DDays to Expiry0.81Extrinsic Value100Contract SizeAmericanOptions Type-0.8087Delta0.0448Gamma18.22Leverage Ratio-0.2041Theta-0.0090Rho-14.73Eff Leverage0.0323Vega
Intraday
- 5D
- Daily
News
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom
Abbott Laboratories' (NYSE:ABT) Investors Will Be Pleased With Their Respectable 43% Return Over the Last Five Years
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135